

# Marco Massari

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1649423/publications.pdf>

Version: 2024-02-01

49  
papers

4,020  
citations

218677

26  
h-index

206112

48  
g-index

51  
all docs

51  
docs citations

51  
times ranked

7467  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tocilizumab in patients with severe COVID-19: a retrospective cohort study. <i>Lancet Rheumatology</i> , The, 2020, 2, e474-e484.	3.9	772
2	Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia. <i>JAMA Internal Medicine</i> , 2021, 181, 24.	5.1	593
3	PD-1 Expression in Acute Hepatitis C Virus (HCV) Infection Is Associated with HCV-Specific CD8 Exhaustion. <i>Journal of Virology</i> , 2006, 80, 11398-11403.	3.4	521
4	Antiviral Intrahepatic T-Cell Responses Can Be Restored by Blocking Programmed Death-1 Pathway in Chronic Hepatitis B. <i>Gastroenterology</i> , 2010, 138, 682-693.e4.	1.3	416
5	Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B. <i>Nature Medicine</i> , 2017, 23, 327-336.	30.7	251
6	Virus-Specific CD8+ Lymphocytes Share the Same Effector-Memory Phenotype but Exhibit Functional Differences in Acute Hepatitis B and C. <i>Journal of Virology</i> , 2002, 76, 12423-12434.	3.4	168
7	Conserved hepatitis C virus sequences are highly immunogenic for CD4+ T cells: Implications for vaccine development. <i>Hepatology</i> , 1999, 30, 1088-1098.	7.3	150
8	Combined Blockade of Programmed Death-1 and Activation of CD137 Increase Responses of Human Liver T Cells Against HBV, But Not HCV. <i>Gastroenterology</i> , 2012, 143, 1576-1585.e4.	1.3	106
9	Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCOVID-19 prospective trial. <i>Journal of Translational Medicine</i> , 2020, 18, 405.	4.4	98
10	Iron reduction and sustained response to interferon-alpha therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study. <i>American Journal of Gastroenterology</i> , 2002, 97, 1204-1210.	0.4	77
11	Transmission of Hepatitis C Virus in a Gynecological Surgery Setting. <i>Journal of Clinical Microbiology</i> , 2001, 39, 2860-2863.	3.9	57
12	Susceptibility and severity of COVID-19 in patients treated with bDMARDs and tsDMARDs: a population-based study. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 986.2-988.	0.9	49
13	Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients. <i>Drug Safety</i> , 2020, 43, 1297-1308.	3.2	48
14	Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation. <i>Critical Care</i> , 2020, 24, 589.	5.8	47
15	Targeting p53 and histone methyltransferases restores exhausted CD8+ T cells in HCV infection. <i>Nature Communications</i> , 2020, 11, 604.	12.8	44
16	Survival of Hospitalized COVID-19 Patients in Northern Italy: A Population-Based Cohort Study by the ITA-COVID-19 Network. <i>Clinical Epidemiology</i> , 2020, Volume 12, 1337-1346.	3.0	42
17	Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study. <i>PLoS ONE</i> , 2017, 12, e0172159.	2.5	42
18	Risk of Guillain-Barré syndrome after 2010-2011 influenza vaccination. <i>European Journal of Epidemiology</i> , 2013, 28, 433-444.	5.7	41

#	ARTICLE	IF	CITATIONS
19	African Sleeping Sickness in Tourists Returning from Tanzania: The First 2 Italian Cases from a Small Outbreak among European Travelers. <i>Clinical Infectious Diseases</i> , 2002, 34, e18-e22.	5.8	37
20	Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. <i>PLoS ONE</i> , 2017, 12, e0185728.	2.5	37
21	Serum Ferritin as a Predictor of Treatment Outcome in Patients With Chronic Hepatitis C. <i>American Journal of Gastroenterology</i> , 2009, 104, 605-616.	0.4	35
22	Treatment optimization and prediction of HCV clearance in patients with acute HCV infection. <i>Journal of Hepatology</i> , 2013, 59, 221-228.	3.7	34
23	Forecasting Hepatitis C liver disease burden on real-life data. Does the <i>hidden iceberg</i> matter to reach the elimination goals?. <i>Liver International</i> , 2018, 38, 2190-2198.	3.9	33
24	Accuracy of CT in a cohort of symptomatic patients with suspected COVID-19 pneumonia during the outbreak peak in Italy. <i>European Radiology</i> , 2020, 30, 6818-6827.	4.5	33
25	Functional reconstitution of HBV-specific CD8 T cells by in vitro polyphenol treatment in chronic hepatitis B. <i>Journal of Hepatology</i> , 2021, 74, 783-793.	3.7	33
26	Abdominal Visceral Infarction in 3 Patients with COVID-19. <i>Emerging Infectious Diseases</i> , 2020, 26, 1926-1928.	4.3	30
27	The impact of chest CT body composition parameters on clinical outcomes in COVID-19 patients. <i>PLoS ONE</i> , 2021, 16, e0251768.	2.5	26
28	Modeling cost-effectiveness and health gains of a "universal" versus "prioritized" hepatitis C virus treatment policy in a real-life cohort. <i>Hepatology</i> , 2017, 66, 1814-1825.	7.3	25
29	Analysis of occult hepatitis B virus infection in liver tissue of HIV patients with chronic hepatitis C. <i>Aids</i> , 2007, 21, 2171-2175.	2.2	21
30	The present profile of chronic hepatitis B virus infection highlights future challenges. <i>Digestive and Liver Disease</i> , 2019, 51, 438-442.	0.9	17
31	Large-Scale Postmarketing Surveillance of Biological Drugs for Immune-Mediated Inflammatory Diseases Through an Italian Distributed Multi-Database Healthcare Network: The VALORE Project. <i>BioDrugs</i> , 2021, 35, 749-764.	4.6	16
32	The value of computed tomography in assessing the risk of death in COVID-19 patients presenting to the emergency room. <i>European Radiology</i> , 2021, 31, 9164-9175.	4.5	14
33	Risk of coronavirus disease 2019 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional disease-modifying anti-rheumatic drugs in Italy. <i>Rheumatology</i> , 2021, 60, SI25-SI36.	1.9	13
34	Association of Influenza Vaccination and Prognosis in Patients Testing Positive to SARS-CoV-2 Swab Test: A Large-Scale Italian Multi-Database Cohort Study. <i>Vaccines</i> , 2021, 9, 716.	4.4	12
35	Contrast-enhanced ultrasound appearance of primary epiploic appendagitis. <i>Journal of Ultrasound</i> , 2014, 17, 75-76.	1.3	10
36	TOCID-19 - A multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia. Study protocol. <i>Contemporary Clinical Trials</i> , 2020, 98, 106165.	1.8	9

#	ARTICLE	IF	CITATIONS
37	Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort. <i>Hepatology International</i> , 2020, 14, 362-372.	4.2	8
38	Hepatitis C virus (HCV) RNA determination after two weeks of induction interferon treatment is an accurate predictor of nonresponse: comparison of two treatment schedules. <i>Digestive Diseases and Sciences</i> , 2001, 46, 2389-2395.	2.3	7
39	Efficacy and risk of rituximab in type II mixed cryoglobulinemia: a significant case report. <i>Digestive and Liver Disease</i> , 2007, 39, S134-S135.	0.9	7
40	Development and validation of a prediction model for tocilizumab failure in hospitalized patients with SARS-CoV-2 infection. <i>PLoS ONE</i> , 2021, 16, e0247275.	2.5	7
41	<p>May 2020: Is It Always COVID-19 No Matter What?</p>. <i>International Medical Case Reports Journal</i> , 2020, Volume 13, 563-567.	0.8	5
42	High-dose glucocorticoids pulse-therapy for beta-coronaviridae pneumonia: a systematic literature review and case-series of Coronavirus disease-2019. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 1119-1125.	0.8	5
43	Effect of Fluoroquinolone Use in Primary Care on the Development and Gradual Decay of Escherichia coli Resistance to Fluoroquinolones: A Matched Case-Control Study. <i>Antibiotics</i> , 2022, 11, 822.	3.7	5
44	Risk of cancer in individuals with alcohol and drug use disorders: a registry-based study in Reggio Emilia, Italy. <i>European Journal of Cancer Prevention</i> , 2020, 29, 270-278.	1.3	4
45	Acute-phase reactants during tocilizumab therapy for severe COVID-19 pneumonia. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 1215-1222.	0.8	3
46	Missed treatment in an Italian HBV infected patients cohort: HBV RER. <i>Digestive and Liver Disease</i> , 2016, 48, 1346-1350.	0.9	2
47	Predictive factors of clinical outcomes in patients with COVID-19 treated with tocilizumab: A monocentric retrospective analysis. <i>PLoS ONE</i> , 2022, 17, e0262908.	2.5	2
48	Iron reduction and sustained response to interferon- $\alpha$ therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study. <i>American Journal of Gastroenterology</i> , 2002, 97, 1204-1210.	0.4	0
49	Methylprednisolone as rescue therapy after tocilizumab failure in patients with severe COVID-19 pneumonia. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 1141.	0.8	0